文献速递烧伤

依诺肝素与普通肝素抗凝预防对烧伤患者急性死亡率的影响

Impact of Heparin and Enoxaparin Anticoagulant Prophylaxis on Improving Acute Mortality in Burn Patients.
PubMed 文献 · J Burn Care Res · 2026-01-01

基于TriNetX数据库的回顾性队列研究纳入26,572例烧伤患者,倾向性评分1:1匹配后比较伤后24小时内仅用普通肝素(UFH)与仅用依诺肝素预防的结局。依诺肝素组(n=7,484)30天死亡率1.3%,低于UFH组(n=7,484)的3.6%(RR=2.70,95%CI 2.15-3.40,P<.05);两组深静脉血栓风险无显著差异。

要点

  • 依诺肝素组30天死亡率为1.3%,低于UFH组的3.6%(RR=2.70,95%CI 2.15-3.40,P<.05)。
  • Kaplan-Meier分析显示依诺肝素组生存概率98.6%,高于UFH组的96.4%(P<.05)。
  • UFH组深静脉血栓风险略高但无统计学意义(RR=1.18,95%CI 0.54-2.54,P=.68)。

核心结论

  • 与UFH相比,依诺肝素预防性抗凝与烧伤患者30天死亡风险显著降低相关。

研究设计与样本

  • 回顾性队列研究,使用TriNetX数据库纳入26,572例烧伤患者。
  • 患者分为伤后24小时内仅接受UFH预防(Cohort 1)与仅接受依诺肝素预防(Cohort 2)两组。
  • 采用1:1倾向性评分匹配校正年龄、性别、族裔、种族、烧伤严重程度、吸入性损伤、糖尿病、急性心肌梗死、卒中及中心静脉导管置入等差异。
  • 匹配后依诺肝素组与UFH组各7,484例。

主要发现

  • 匹配后依诺肝素组30天死亡率为1.3%,UFH组为3.6%(RR=2.70,95%CI 2.15-3.40,P<.05)。
  • Kaplan-Meier分析显示依诺肝素组生存概率98.6%,高于UFH组的96.4%(P<.05)。
  • UFH组深静脉血栓风险略高于依诺肝素组,但无统计学意义(RR=1.18,95%CI 0.54-2.54,P=.68)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Burn patients have a higher chance of developing thromboembolic complications, leading to worsened mortality rates, so prophylactic anticoagulation is important. Anticoagulants such as enoxaparin, a low-molecular-weight heparin, and unfractionated heparin (UFH) have been frequently used as chemical prophylactic treatments of thromboembolism. Enoxaparin has been shown to have lower mortality and higher efficacy in surgical patients and coronary artery disease patients. The aim of the study is to assess mortality and compare the safety of enoxaparin and heparin in acute burn patients. A retrospective cohort study of 26,572 burn patients was conducted using the TriNetX database. Patients were divided into 2 cohorts: those receiving only UFH (Cohort 1) and those receiving only enoxaparin (Cohort 2) prophylaxis within 24 hours after burn injury. Cohorts were matched with 1:1 propensity score matching to correct for differences in age, gender, ethnicity, race, burn severity, inhalation injury, diabetes mellitus, acute myocardial infarction, stroke, and central line venous catheter placement. Outcomes assessed included mortality and deep vein thrombosis within a month (30 days). After matching, the enoxaparin (n = 7,484) cohort showed significantly lower 30-day mortality (1.3%) compared to the UFH (n = 7,484) cohort (3.6%) (risk ratio [RR] = 2.70, 95% CI: 2.15-3.40, P < .05). Kaplan-Meier analysis demonstrated a higher survival probability in the enoxaparin group (98.6% vs 96.4%, P < .05). DVT risk was slightly higher with UFH but not statistically significant (RR = 1.18, 95% CI: 0.54-2.54, P = .68). Prophylactic anticoagulation with enoxaparin is associated with a significant lower 30-day mortality risk compared to UFH.

来源:J Burn Care Res,查看原文。版权归原作者所有。

引用

  1. Patel MM, Lim SE, Cuello VA, et al. Impact of Heparin and Enoxaparin Anticoagulant Prophylaxis on Improving Acute Mortality in Burn Patients. J Burn Care Res. 2026. PMID: 40355368. doi:10.1093/jbcr/iraf080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。